Characteristics of patients receiving allergy vaccination: To which extent do socio-economic factors play a role?

European Journal of Public Health

Volumn 21, Issue 3, 2011, Pages 323-328

  Petersen, Karin Dam ^a,f   Kronborg, Christian ^a   Gyrd Hansen, Dorte ^a,d   Dahl, Ronald ^b   Larsen, Jørgen Nedergaard ^c   Linneberg, Allan ^e  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ALK ABELLÓ   (Denmark)

^d Dansk Sundhedsinstitut   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

asthma; hay fever; health services needs and demand; immunological desensitization; quality of life

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASTHMA; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DENMARK; DESENSITIZATION; EDUCATIONAL STATUS; FEMALE; HAY FEVER; HEALTH SERVICE; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PAIN ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SOCIOECONOMICS; UTILIZATION REVIEW; VACCINATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGE FACTORS; AGED; ASTHMA; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; DESENSITIZATION, IMMUNOLOGIC; EDUCATIONAL STATUS; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; VACCINATION;

EID: 79957477707     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckq063     Document Type: Article

References (28)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64. (Pubitemid 39504428)
2. Jarvis D, Luczynska C, Chinn S, et al. Change in prevalence of IgE sensitization and mean total IgE with age and cohort. J Allergy Clin Immunol 2005;116:675-82. (Pubitemid 41267146)
3. Petersen KD, Kronborg C, Gyrd-Hansen D, et al. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy 2008;63:284-91. (Pubitemid 351224679)
4. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseasesA WHO position paper. J Allergy Clin Immunol 1998;102:558-62.
5. varez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82): 1-20.
6. Bousquet J, Demoly P. Specific immunotherapy-an optimistic future. Allergy 2006;61:1155-8.
7. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;4:CD001186.
8. Dam PK, Gyrd-Hansen D, Kjaergaard S, Dahl R. Clinical and patient based evaluation of immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005;33:264-9. (Pubitemid 41769445)
9. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005;33:296-302. (Pubitemid 47250520)
10. Horne R, Price D, Cleland J, et al. Can asthma control be improved by understanding the patient's ssperspective? BMC Pulm Med 2007;7:8.
11. Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med 2006;100:354-62. (Pubitemid 43078990)
12. Petersen KD, Gyrd-Hansen D, Linneberg A, et al. Willingness to pay for allergy-vaccination among Danish patients with respiratory allergy. Int J Technol Assess Health Care 2010;26:20-9.
13. Linneberg A, Bodtger U. The use of grass pollen-specific immunotherapy among grass pollen allergic rhinitis in the general population. Allergy 2007;62:825-6. (Pubitemid 46934364)
14. The Danish Medicines Agency. Statistik for lægemidler og lægemiddelgrupper. Available at: http://www.medstat.dk/ MedStatDataViewer.php. (19 September 2008, date last accessed).
15. Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy 2005;60:1357-60. (Pubitemid 41476177)
16. Grossman M. On the concept of health capital and the demand for health. J Polit Econ 1972;80:223-55.
17. Mooney G. Economics, medicine and health care, 3rd edn. Dorchester, Dorset: Pearson Education Limited, 2003.
18. Folland S, Goodman AC, Stano M. The economics of health and health care, 4th edn. Oakland: Prentice Hall, 2004.
19. Viscusi WP, Moore MJ. Rates of time preference and valuations of the duration of life. J Public Econ 1989;38:297-317.
20. Bousquet J, van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-S334.
21. Bachert C, van CP. The WHO ARIA (allergic rhinitis and its impact on asthma) initiative. Chem Immunol Allergy 2003;82:119-26. (Pubitemid 38063271)
22. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30(Suppl 1): 2-5. (Pubitemid 30341369)
23. Bousquet J, Clark TJ, Hurd S, et al. GINA guidelines on asthma and beyond. Allergy 2007;62:102-12. (Pubitemid 46091634)
24. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
25. Pedersen KM, Wittrup-Jensen K, Brooks R, Guidex C. Værdisæ tning af sundhed. Teorien om kvalitetsjusterede levea°r og en dansk anvendelse (Valuation of health. Theory of quality adjusted life years). Odense: University of Southern Denmark, (in Danish), 2006.
26. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17:13-35. (Pubitemid 30072853)
27. Le CT, Boen JR. Health and number: basic biostatistical methods. New York: Wiley-Liss, Inc, 1995.
28. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1997.